Redalpine

ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of novel human immunomodulatory proteins aimed at enhancing cancer treatment and addressing autoimmune diseases. By focusing on next-generation therapeutics, ImmunOs aims to create drugs that not only exhibit direct anti-tumor effects but also remodel the tumor microenvironment. Additionally, the company is developing antibodies designed to block the activation of specific HLA molecules associated with autoimmune conditions. Through its innovative approach, ImmunOs Therapeutics seeks to improve the lives of patients suffering from serious diseases.

Relai AG is a Swiss company based in Zurich that specializes in a Bitcoin investment application, established in 2019. The app allows users to conveniently invest in Bitcoin, functioning as a digital ATM for cryptocurrency. It enables users to buy and sell Bitcoin directly from their bank accounts within one minute, without the need for registration, onboarding, or KYC verification. Additionally, the platform offers an auto-invest feature, ensuring high-security standards while allowing users to manage their investments efficiently. Relai aims to make Bitcoin investment accessible to everyone, streamlining the process and enhancing user experience.

Daedalean AG, founded in 2016 and based in Zurich, Switzerland, specializes in developing autonomous flight control systems for electric personal aircraft. The company focuses on creating guidance, navigation, and control software that aims to replace and enhance the capabilities of human pilots. By working on solutions for both current civil aircraft and the future of advanced aerial mobility, Daedalean is positioning itself at the forefront of aviation technology innovation.

Relai AG is a Swiss company based in Zurich that specializes in a Bitcoin investment application, established in 2019. The app allows users to conveniently invest in Bitcoin, functioning as a digital ATM for cryptocurrency. It enables users to buy and sell Bitcoin directly from their bank accounts within one minute, without the need for registration, onboarding, or KYC verification. Additionally, the platform offers an auto-invest feature, ensuring high-security standards while allowing users to manage their investments efficiently. Relai aims to make Bitcoin investment accessible to everyone, streamlining the process and enhancing user experience.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in antibody discovery and immune repertoire analysis through its innovative MemoMAB platform. This technology enables the creation of a recombinant in vitro copy of an individual’s B cell and antibody repertoire, resulting in unique and extensive libraries that reflect a person's immune response. These libraries are anticipated to contain a significant number of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics employs its MemoMAB platform in proprietary antibody lead discovery programs and offers it for collaboration with other entities, enhancing the potential for novel therapeutic developments.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, that specializes in developing antibody-drug conjugate (ADC) linker technology for targeted chemotherapy. Founded in 2019, the company focuses on creating a platform that facilitates the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines. This approach allows for the direct use of "off-the-shelf" antibodies, enabling the site-specific modification of ADCs within days, while ensuring robust quality control and analysis. Araris' technology is designed to deliver potent drugs directly to cancer cells, minimizing exposure to healthy tissues and thereby improving safety and tolerability for patients. The company's innovative ADC technology is supported by two patents, underscoring its commitment to advancing anti-cancer treatment options.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of novel human immunomodulatory proteins aimed at enhancing cancer treatment and addressing autoimmune diseases. By focusing on next-generation therapeutics, ImmunOs aims to create drugs that not only exhibit direct anti-tumor effects but also remodel the tumor microenvironment. Additionally, the company is developing antibodies designed to block the activation of specific HLA molecules associated with autoimmune conditions. Through its innovative approach, ImmunOs Therapeutics seeks to improve the lives of patients suffering from serious diseases.

EraCal therapeutics AG engages in drug discovery to treat different diseases. The company develops drugs to treat obesity and its comorbidities. EraCal therapeutics AG was founded in 2018 and is based in Schlieren, Switzerland.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, it originated as a spin-off from ETH Zurich. The company's lead candidate, VS-01, is in preclinical development and aims to address acute liver disease while supporting multiple failing organs, targeting three rare indications and having received Orphan Drug Designation for acute liver failure. Versantis also has products in its pipeline, including VS-02 and VS-03, which are designed to treat chronic liver diseases and drug intoxications, respectively. These treatments aim to meet significant unmet medical needs and have the potential to enhance patient outcomes across various medical fields.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, that specializes in developing antibody-drug conjugate (ADC) linker technology for targeted chemotherapy. Founded in 2019, the company focuses on creating a platform that facilitates the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines. This approach allows for the direct use of "off-the-shelf" antibodies, enabling the site-specific modification of ADCs within days, while ensuring robust quality control and analysis. Araris' technology is designed to deliver potent drugs directly to cancer cells, minimizing exposure to healthy tissues and thereby improving safety and tolerability for patients. The company's innovative ADC technology is supported by two patents, underscoring its commitment to advancing anti-cancer treatment options.

Daedalean AG, founded in 2016 and based in Zurich, Switzerland, specializes in developing autonomous flight control systems for electric personal aircraft. The company focuses on creating guidance, navigation, and control software that aims to replace and enhance the capabilities of human pilots. By working on solutions for both current civil aircraft and the future of advanced aerial mobility, Daedalean is positioning itself at the forefront of aviation technology innovation.

RosieReality is a company based in Zurich, Switzerland, founded in 2017, that develops an educational application named Rosie for children aged nine and older. The app utilizes augmented reality to enhance early childhood education, allowing children to engage with the learning material in an interactive way. Through the app, users can program Rosie the Robot by using magical 3D shapes to solve various augmented reality puzzles, making the learning experience both fun and educational for curious young minds.

TOLREMO therapeutics AG, a biotechnology company, develops drug discovery engine and therapies to patients with cancer. The company was incorporated in 2017 and is based in Muttenz, Switzerland.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in antibody discovery and immune repertoire analysis through its innovative MemoMAB platform. This technology enables the creation of a recombinant in vitro copy of an individual’s B cell and antibody repertoire, resulting in unique and extensive libraries that reflect a person's immune response. These libraries are anticipated to contain a significant number of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics employs its MemoMAB platform in proprietary antibody lead discovery programs and offers it for collaboration with other entities, enhancing the potential for novel therapeutic developments.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, it originated as a spin-off from ETH Zurich. The company's lead candidate, VS-01, is in preclinical development and aims to address acute liver disease while supporting multiple failing organs, targeting three rare indications and having received Orphan Drug Designation for acute liver failure. Versantis also has products in its pipeline, including VS-02 and VS-03, which are designed to treat chronic liver diseases and drug intoxications, respectively. These treatments aim to meet significant unmet medical needs and have the potential to enhance patient outcomes across various medical fields.

Bexio AG is a Swiss-based company that specializes in developing cloud-based business and accounting software aimed at small and medium-sized enterprises. Founded in 2013 and headquartered in Rapperswil, Switzerland, Bexio offers a platform designed to simplify accounting and business management processes. The software provides a standardized interface that enhances customer acquisition and facilitates connections with trustees, banks, and service providers. In September 2015, the company rebranded from its former name, easySYS AG, and as of July 2018, it operates as a subsidiary of Schweizerische Mobiliar Versicherungsgesellschaft AG. Through its innovative solutions, Bexio supports small businesses in managing their financial operations more efficiently.

Knip AG, founded in September 2013 by Dennis Just and Christina Kehl, is a Zurich-based company specializing in mobile insurance management. The Knip app allows users to efficiently track their insurance policies, premiums, and benefits. Users receive biannual financial reviews to help them compare tariffs and products. The company employs over 100 staff members across Zurich, Berlin, and Belgrade, and provides personalized advice on various insurance matters. Users can electronically adjust their premiums, initiate new policies, or cancel existing ones, all while benefiting from the company's commitment to transparency and unbiased guidance. Knip AG was acquired by Komparu B.V. in June 2017 and is backed by venture capital from the U.S., Switzerland, Germany, and the Netherlands. The company is also registered with the German Chamber of Industry & Commerce and certified by the German Technical Inspection Agency.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in antibody discovery and immune repertoire analysis through its innovative MemoMAB platform. This technology enables the creation of a recombinant in vitro copy of an individual’s B cell and antibody repertoire, resulting in unique and extensive libraries that reflect a person's immune response. These libraries are anticipated to contain a significant number of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics employs its MemoMAB platform in proprietary antibody lead discovery programs and offers it for collaboration with other entities, enhancing the potential for novel therapeutic developments.

easySYS AG is a business software for small businesses and the self-employed.

Bexio AG is a Swiss-based company that specializes in developing cloud-based business and accounting software aimed at small and medium-sized enterprises. Founded in 2013 and headquartered in Rapperswil, Switzerland, Bexio offers a platform designed to simplify accounting and business management processes. The software provides a standardized interface that enhances customer acquisition and facilitates connections with trustees, banks, and service providers. In September 2015, the company rebranded from its former name, easySYS AG, and as of July 2018, it operates as a subsidiary of Schweizerische Mobiliar Versicherungsgesellschaft AG. Through its innovative solutions, Bexio supports small businesses in managing their financial operations more efficiently.

Redbiotec is a private biotech company in Zurich-Schlieren. Founded in 2006 as a spin-off of ETH Zürich, the company has won several awards and is backed by experienced institutional and private investors. During its era as a vaccine innovator, Redbiotec has sold its CMV vaccine business to Pfizer in 2015 and also created an HSV-2 immunotherapy. Presently, Redbiotec is dedicated to developing bacteria-based gene therapies to treat cancer and genetic disorders. The proprietary bacteria platform accommodates large and diverse therapeutic cargos and is designed to overcome many delivery hurdles faced by other vehicles.

Knip AG, founded in September 2013 by Dennis Just and Christina Kehl, is a Zurich-based company specializing in mobile insurance management. The Knip app allows users to efficiently track their insurance policies, premiums, and benefits. Users receive biannual financial reviews to help them compare tariffs and products. The company employs over 100 staff members across Zurich, Berlin, and Belgrade, and provides personalized advice on various insurance matters. Users can electronically adjust their premiums, initiate new policies, or cancel existing ones, all while benefiting from the company's commitment to transparency and unbiased guidance. Knip AG was acquired by Komparu B.V. in June 2017 and is backed by venture capital from the U.S., Switzerland, Germany, and the Netherlands. The company is also registered with the German Chamber of Industry & Commerce and certified by the German Technical Inspection Agency.

Restorm AG operates an online music platform, restorm.com, that connects various stakeholders in the music industry, including artists, clubs, promoters, record labels, media representatives, and fans. Founded in 2007 and based in Solothurn, Switzerland, the platform enables music fans to stream or download music, share their musical preferences, and engage with other users. It serves as a hub for bands and labels to promote their work, while event managers and venues can advertise concert opportunities. Additionally, fans have the chance to support their favorite musicians, fostering a vibrant community that enhances the music experience for all participants. Restorm.com aims to facilitate collaboration and discovery within the music world, catering to the diverse needs of its users.

Questli is a web and mobile game platform to play and create quests. Solve tasks, learn new stuff, earn points & prizes, challenge your friends and have fun anytime anywhere! 1600+ amazing causal quests to enjoy.

InSphero AG develops organotypic biological 3D microtissues and microtissue-based assays for biochemical compounds screening and predictive drug testing applications. It offers human prostate and mammary carcinoma, and rat liver microtissues. The company also provides compound toxicity testing, cell-invasion assays, stem-cell research, cell-to-cell interaction, regenerative medicine, tissue engineering, and cell-to-extracellular matrix interaction services. In addition, it involves in study of transcriptomics, proteomics, and metabolomics. Further, the company provides custom development services, which include microtissue development, H and E stained paraffin sections, growth characteristics data, and morphometric data. Its microtissue system enables the generation of various model systems using either tumor-derived cells to reconstitute primary tumors or primary cells to mimic structure and function of diverse organ tissues. InSphero AG was founded in 2009 and is based in Zurich, Switzerland.

Redvax is a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. Redvax is a preclinical stage company. The company develops multi-component virus-like particles (VLPs) and other protein assemblies for vaccine development in the field of CMV and a further undisclosed field.